| Name | Title | Contact Details |
|---|---|---|
Gintas Vildzius |
Senior Vice President and Chief Technology Officer | Profile |
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and
EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.